Biogen's Early-Stage Alzheimer's Data Continues to Impress Post author:Sam Post published:November 1, 2017 Post category:BioPharma ALZ’s researchers continue to see hope in Biogen’s aducanumab. Source: BioSpace You Might Also Like A Peek Behind the Curtain of the Ariad-Takeda Deal January 19, 2017 Oxford BioMedica Wins $105M Gene Therapy Contract From Bioverativ February 14, 2018 Don't Count Us Out: Pfizer Hints at a Possible Bristol-Myers Squibb Deal May 2, 2017
